The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: A double-blinded, randomized, placebo-controlled trial

Arthritis Research and Therapy

Volumn 19, Issue 1, 2017, Pages

  Izumi, Yasumori ^a   Akazawa, Manabu ^b   Akeda, Yukihiro ^c   Tohma, Shigeto ^a   Hirano, Fuminori ^a   Ideguchi, Haruko ^a   Matsumura, Ryutaro ^a   Miyamura, Tomoya ^a   Mori, Shunsuke ^a   Fukui, Takahiro ^a   Iwanaga, Nozomi ^a   Jiuchi, Yuka ^a   Kozuru, Hideko ^a   Tsutani, Hiroshi ^a   Saisyo, Kouichirou ^a   Sugiyama, Takao ^a   Suenaga, Yasuo ^a   Okada, Yasumasa ^a   Katayama, Masao ^a   Ichikawa, Kenji ^a   Furukawa, Hiroshi ^a   Kawakami, Kenji ^a   Oishi, Kazunori ^d   Migita, Kiyoshi ^a,e   more..

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Interstitial lung disease; Pneumococcal polysaccharide vaccine; Pneumonia; Rheumatoid arthritis

Indexed keywords

ABATACEPT; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISOLONE; PREDNISONE; SODIUM CHLORIDE; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFECTION RATE; INFECTION RISK; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STREPTOCOCCUS PNEUMONIA; AGED; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; KAPLAN MEIER METHOD; MICROBIOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PHYSIOLOGY; PNEUMONIA, PNEUMOCOCCAL; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; STREPTOCOCCUS PNEUMONIAE;

AGED; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE;

EID: 85010458368     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1207-7     Document Type: Article

References (31)

1. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287-93.
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85.
3. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:871-83.
4. van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011;10:341-52.
5. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414-22.
6. Diao WQ, Shen N, Yu PX, Liu BB, He B. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials. Vaccine. 2016;34:1496-503.
7. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340:c1004.
8. Glück T, Müller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008;46:1459-65.
9. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1, CD000422.
10. Perry LM, Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep. 2014;16:431.
11. Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther. 2015;17:149.
12. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013;52:53.
13. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007;66:1221-6.
14. Wiemken TL, Carrico RM, Klein SL, Jonsson CB, Peyrani P, Kelley RR, et al. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine. 2014;32:2198-203.
15. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged≥60years: 3years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014;58:909-17.
16. Sinclair A, Xie X, Teltscher M, Dendukuri N. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol. 2013;51:2303-10.
17. Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;(11):CD001390.
18. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362:812-22.
19. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study. Hum Vaccin Immunother. 2012;8:639.
20. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;23, CD000422.
21. Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Vaccine. 2015;33 Suppl 4:D60-5.
22. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-300.
23. Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39:360-7.
24. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. 2011;13:R139.
25. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52:53-61.
26. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258-65.
27. Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:2847-55.
28. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics-a large multicentre UK study. Rheumatology (Oxford). 2014;53:1676-82.
29. Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tuder R, Cool CD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med. 2013;107:1247-52.
30. Lake F, Proudman S. Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Semin Respir Crit Care Med. 2014;35:222-38.
31. Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheum. 2016;68:56-66.